Qmetrics Technologies and 20/15 Visioneers Announce Go-to-Market Partnership
07 Jul 2022
mTBI (Mild Traumatic Brain Injury)
Concussion Index
Safer return to activities and sports
PITTSFORD, N.Y. and HEREFORD, Pa., July 7, 2022 /PRNewswire/ -- Today, 20/15 Visioneers LLC., a leading, advanced science and technology management consulting and marketing services company and Qmetrics Technologies, a leader in medical image analysis, announced a partnership to introduce an innovative assessment of mTBI/concussion severity.
Qmetrics' Concussion Index delivers a number derived from multiple 3D features of a single conventional MRI exam that provides an objective indicator of post-concussive microtrauma severity. The higher the number, the more severe the post-concussive injury.
Concussions or mTBI in sports has lead to behavioral changes and premature and tragic deaths for too many athletes
Tweet this
"Concussions are largely diagnosed and managed via patient symptoms," says
Edward Schreyer, CEO, Qmetrics Technologies. "Post-concussive brain injuries are typically too subtle to be seen by the human eye. Our technology-driven Concussion Index uses algorithms to identify post-concussive injuries. As a parent of two kids who play contact sports, I'm excited that we are partnering with 20/15 Visioneers to raise awareness of this objective assessment of concussions. Hopefully, it will lead to improved management of mTBI and better long-term outcomes."
"20/15 Visioneers is an in silico-first leader in consulting and has discovered the life-changing capabilities that Qmetrics' patented Artificial Intelligence and Machine Learning technology can do for concussion patients and athletes. This innovative technology can improve concussive understanding and time to heal and ultimately enhance the safety of many contact sports and potentially prevent CTE. "
John F. Conway, Chief Visioneer Officer, 20/15 Visioneers.
Read the Whitepaper "Is it Safe to Play Again" here:
https://www.20visioneers15.com/blog
Free registration for the interactive webinar here:
https://us02web.zoom.us/webinar/register/WN_vnrLcNLFTjemB_LxjL1tZQ
About Qmetrics Technologies
Qmetrics Technologies is a specialized medical imaging service organization that delivers high-quality medical image-based services and products to the healthcare, pharmaceutical, biotechnology, and medical device industries. Its accurate image segmentation, 3D modeling, and quantitative analysis provide a powerful combination of scientific and medical expertise, allowing clients to determine therapeutic efficacy more efficiently with precise, reliable and measurable results. Qmetrics' proprietary software includes the DiscernAI™ Machine Learning capability that can help discover relationships between imaging, clinical and genetic factors and study outcomes, helping customers better understand therapeutic effects. Co-founded by Dr. Saara Totterman and Dr. José Tamez-Peña, Qmetrics is a privately held company based in Pittsford, NY, which provides services internationally. Visit www.qmetricstech.com for more information.
About 20/15 Visioneers
20/15 Visioneers is a science and technology management consulting and marketing services think tank. We are "Visioneering" next-generation science and technology methods and approaches. Our client-base includes but is not limited to early to late research and development, clinical, healthcare, and materials organizations. See www.20visioneers15.com for more information.
SOURCE 20/15 Visioneers
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.